MSH2 and neoplasm: Furthermore, MSH2 may suppress homologous recombination (HR) via regulation of RAD51; therefore, for LS patients increased HR activity may result in increased resistance to radiotherapy and these resistant tumors may have increased rates of IR-induced genetic instability, elevated tumor heterogeneity and subsequently more malignant and invasive tumors [52].